Adamas Announces Positive Results from Ph III Study of Gocovri in Parkinson’s Patients with Dyskinesia

Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) On 4/19/18 announced positive data from EASE LID 2, the company’s two-year Phase 3 open-label study of GOCOVRI™ (amantadine) extended release capsules, the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.